


attach  
paper 1a  
PTO/SB/052 (10-96)

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>		
		Application Number	09/720,371	
		Filing Date	December 26, 2000	
		First Named Inventor	Keld KALTOFT	
		Group Art Unit		
		Examiner Name		
Sheet	1	6	Attorney Docket Number	KALTOFT1



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code? (if known)			
DAJ ↓	AA	5 1 8 8 9 5 9		HABERMAN	02-23-1993	
	AB	5 8 2 7 6 4 2		RIDDELL, et al.	10-27-1998	
	AC	5 9 8 9 5 4 6		LENARDO	11-23-1999	
	AD	6 0 0 8 0 4 4		COTROPIA	12-28-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)				
	AE	WO	8 8 0 7 0 7 7		LIU, et al.	09-22-1988		
✓	AF	WO	9 4 0 2 1 5 6		ENGELMAN, et al.	02-03-1994		
✓	AG	WO	9 6 0 1 1 2 2		BOUSSIOTIS, et al.	01-18-1996		
	AH	WO	9 6 0 6 6 3 0		SERCARZ, et al.	03-07-1996		
	AI	WO	9 7 0 5 2 3 9		GRUENBERG, et al.	02-13-1997		
✓	AJ	WO	9 7 4 6 2 5 6		WEBB, et al.	12-11-1997		

Examiner Signature	<i>Dan A. Saunders</i>	Date Considered	5/14/03
-----------------------	------------------------	--------------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/720,371
				Filing Date	December 26, 2000
				First Named Inventor	Keld KALTOFT
				Group Art Unit	
				Examiner Name	
Sheet	2	of	6	Attorney Docket Number	KALTOFT1


OTHER PRIOR ART- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AK	WILSON, "The Complete Guide to Inflammatory Diseases", Scrip Reports, 1997, 5-203, PJB Publications Ltd., United Kingdom	
	AL	KOUTROBAKIS, et al., "Immunogenetics of Cytokines," Scand. J. Gastroenterol., 1995, 1139-1146, 30	
		JEWELL, et al., "Cytokine and Adhesion Molecules," Research and Clinical Forums, 19..., 187-192, 17(1)	
	AN	ELSON, et al., "Experimental Models of Inflammatory Bowel Disease," Gastroenterology, 1995, 1344-1367, 109	
	AO	TILG, "New Insights into the Mechanisms of Interferon Alfa: An Immunoregulatory and Anti-inflammatory Cytokine," Gastroenterology, 1997, 1017-1021, 112	
	AP	SATSANGI, et al., "Contribution of Genes of the Major Histocompatibility Complex to Susceptibility and Disease Phenotype in Inflammatory Bowel Disease," The Lancet, 1994, 1212-1217, 347	
	AQ	JONES, et al., "Peripheral Clonal Elimination of Functional T Cells," Science, 1990, 1726-1729, 250	
	AR	PENDER, et al., "Proteolytic Degradation of Intestinal Mucosal Extracellular Matrix after Lamina Propria T cell Activation," Gut, 1996, 284-290, 39	
	AS	BRUCE, et al., "Oral Immunization and Oral Tolerance," Regulation, Chapter 9 171-183	
	AT	SCHREIBER, et al., "Activation of Nuclear Factor KB in Inflammatory Bowel Disease," Gut, 1998, 477-484, 42	
	AU	KALTOFT, et al., "Common Clonal Chromosome Aberrations in Cytokine-Dependent Continuous Human T-Lymphocyte Cell Lines," Cancer Genet. Cytogenet., 1995, 68-71, 85 <i>uf4</i>	
	AV	ROBIJN, et al., "Phenotypic and Molecular Characterization of Human Monoclonal TCRγ/δ T-Cell Lines from Jejunum and Colon of Healthy Individuals," Scand. J. Immunol., 1993, 247-253, 38	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Application Number	09/720,371	
		Filing Date	December 26, 2000	
		First Named Inventor	Keld KALTOFT	
		Group Art Unit		
		Examiner Name		
Sheet	3	6	Attorney Docket Number	KALTOFT1




OTHER PRIOR ART- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the document (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AW	GROUX, et al., "A CD4 <sup>+</sup> T-cell Subset Inhibits Antigen-Specific T-cell Responses and Prevents Colitis," Nature, 1997, 737-742, 389	
	AX	VINCENT, "Search for Effective Immunomodulating Strategies Against Sepsis," Commentary, 1998, 922-923, 351	
	AY	BYRNSKOV, "Cyclosporin in Crohn's Disease Therapeutic and Pathogenetic Implications," Danish Medical Bulletin, 1994, 332-344, 41(3)	
	AZ	PERILLO, et al., "Human T Lymphocytes Possess a Limited in Vitro Life Span," Experimental Gerontology, 1989, 177-187, 24	
	BA	GROSS, et al., "Distribution of Dominant T Cell Receptor $\beta$ Chains in Human Intestinal Mucosa," J. Exp. Med., 1994, 1337-1344, 180	
ref	BB	KALTOFT, et al., "Establishment of Two Continuous T-cell Strains from a Single Plaque of a Patient with Mycosis Fungoides," In Vitro Cell. Dev. Biol., 1992, 161-167, 28A	
	BC	MOWAT, "The Regulation of Immune Responses to Dietary Protein Antigens," 1987, 93-98, 8(3)	
	BD	WEBB, et al., "Extrathymic Tolerance of Mature T cells: Clonal Elimination as a Consequence of Immunity," Cell, 1990, 1249-1256, 63	
	BE	DEL PRETE, et al., "Human IL-10 is Produced by Both Type 1 Helper (Th1) and Type 2 Helper (Th2) T Cell Clones and Inhibits Their Antigen-Specific Proliferation and Cytokine Production," 1993, 353-360, 150(2)	
	BF	SCHWARTZ, et al., "A Cell Culture Model for T Lymphocyte Clonal Anergy," Science, 1990, 1349-1356, 248	
	BG	NIKOLAUS, et al., "Increased Secretion of Pro-Inflammatory Cytokines by Circulating Polymorphonuclear Neutrophils and Regulation by Interleukin 10 During Intestinal Inflammation," Gut, 1998, 470-476, 42	
ref	BH	KALTOFT, et al., "In Vitro Genetically Aberrant T-cell Clones with Continuous Growth are Associated with Atopic Dermatitis," Arch. Dermatol. Res., 1994, 42-47, 287	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/720,371
		Filing Date	December 26, 2000
		First Named Inventor	Keld KALTOFT
		Group Art Unit	
		Examiner Name	
Sheet 4	of 6	Attorney Docket Number	KALTOFT1



## OTHER PRIOR ART- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BI	PERDUE, et al., "Mucosal Regulators and Immunopathophysiology," Current Opinion in Gastroenterology, 1996, 591-599, 12	
ref	BJ	KALTOFT, "Cytokine Driven Immortalization of in vitro Activated Human T Lymphocytes, CD28 Expression Correlates Inversely with Cell Population Doublings," Exp. Clin. Immunogenet., 405 reprint, 1-7 <i>cannot find this</i>	
	BK	CAROL, "Spontaneous Secretion of Interferon $\gamma$ and Interleukin 4 by Human Intraepithelial and Lamina Propria Gut Lymphocytes," Gut, 1998, 643-649, 42	
	BL	WATANABE, et al., "Altering Cytokine Soups: A Recipe for Inflammatory Bowel Disease," Gut, 1998, 607-608, 42	
	BM	O'FARRELLY, "Just how Inflamed is the Normal Gut," Gut, 1998, 603-606, 42	
	BN	KALTOFT, et al., "Cytogenetic Findings in Cell Lines from Cutaneous T-cell Lymphoma," Dermatologic Clinics, 1994, 295-304, 12(2)	
	BO	KALTOFT, et al., "Appearance of Isochromosome 18q can be Associated with In Vitro Immortalization of Human T Lymphocytes," Cancer Genet. Cytogenet., 1995, 13-16, 81	
ref	BP	KALTOFT, et al., "A Continuous t-cell Line from a Patient with Sézary Syndrome," Arch. Dermatol. Res., 1987, 293-298, 279 <i>T-cell</i>	
ref	BQ	KALTOFT, et al., "Sézary Syndrome is Characterized by Genotraumatic T cells," Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin, 1994, 401-418, Plenum Press, New York	
	BR	EFFROS, et al., "Replicative Senescence of T cells: does the Hayflick Limit Lead to Immune Exhaustion," Immunology Today, 1997, 450-454, 18(8)	
	BS	ELEWAUT, et al., "Distinctive Activated Cellular Subsets in Colon from Patients with Crohn's Disease and Ulcerative Colitis," Scand. J. Gastroenterol., 1998, 743-748, 33	
	BT	DUCHMANN, et al., "Tolerance Exists Towards Resident Intestinal Flora but is Broken in Active Inflammatory Bowel Disease (IBD)," Clin. Exp. Immunol., 1995, 448-455, 102	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		Application Number	09/720,371
		Filing Date	December 26, 2000
		First Named Inventor	Keld KALTOFT
		Group Art Unit	
		Examiner Name	
Sheet 5	of 6	Attorney Docket Number	KALTOFT1

OTHER PRIOR ART- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	BU	STRONKHORST, et al., "CD4 Antibody Treatment in Patients with Active Crohn's Disease: a Phase 1 Dose Finding Study," Gut, 1997, 320-327, 40	
	BV	TARGAN, et al., "A Short-term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor $\alpha$ for Crohn's Disease," The New England Journal of Medicine, 1997, 1029-1035, 337	
	BW	KAY, et al., "Role of T Cells in Asthma", Chem Immunol., 1998, 178-191, 71	
	BX	ROLFE, et al., "Cyclosporin A and FK506 Reduce Interleukin-5 mRNA Abundance by Inhibiting Gene Transcription," Am. J. Respir. Cell Mol. Biol. 1997, 243-250, 17	
	BY	MEDAER, et al., "Depletion of Myelin-Basic-Protein Autoreactive T cells by T-cell Vaccination: Pilot Trial in Multiple Sclerosis," 1995, 807-808, 346	
	BZ	ZHANG, et al., "MHC-Restricted Depletion of Human Myelin Basic Protein-Reactive T cells by T Cell Vaccination," Science, 1993, 1451-1454, 261	
	CA	ROSENBERG, et al., "Treatment of Patients with Metastatic Melanoma with Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2," Journal of the National Cancer Institute, 1994, 1159-1166, 86(15)	
	CB	SMART, et al., "T Lymphocytes of the Human Colonic Mucosa: Functional and Phenotypic Analysis," Clin. Exp. Immunol., 1988, 63-69, 73	
	CC	COTTREZ, et al., "Analysis of the V $\beta$ Specificity of Superantigen Activation with a Rapid and Sensitive method using RT PCR and an Automatic DNA Analyser," Journal of Immunological Methods, 1994, 85-94, 172	
	CD	PAWELEC, et al., "Human T-cell Clones in Long-term Culture as a Model of Immunosenesence," Immunological Reviews, 1997, 31-42, 160	
	CE	LIONETTI, et al., "T-cell Activation Can Induce Either Mucosal Destruction or Adaptation in Cultured Human Fetal Small Intestine," Gastroenterology, 1993, 373-381, 105	
	CF	DEEM, et al., "Triggered Human Mucosal T cells Release Tumour Necrosis Factor-alpha and Interferon-Gamma Which Kill Human Colonic Epithelial Cells," Clin. Exp. Immunol., 1991, 79-84, 83	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/720,371
				Filing Date	December 26, 2000
				First Named Inventor	Keld KALTOFT
				Group Art Unit	
				Examiner Name	
Sheet	6	of	6	Attorney Docket Number	KALTOFT1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	CG	PLEVY, et al., "A Role for TNF- $\alpha$ and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease," The Journal of Immunology, 1997, 6276-6282, 159	
	CH	SCHREIBER, et al., "The Mechanism of Action of Cyclosporin A and FK506," Immunology Today, 1992, 136-142, 13(4)	
		SCHREIBER, et al., "Tumour Necrosis Factor $\alpha$ and Interleukin 1 $\beta$ in Relapse of Crohn's Disease," The Lancet, 1999, 459-461, 353	
	CJ	AVERSA, et al., "The 26-kD Transmembrane Form of Tumor Necrosis Factor $\alpha$ on Activated CD4 <sup>+</sup> t Cell Clones Provides a Costimulatory Signal for Human B Cell Activation," J. Exp. Med., 1993, 1575-1585, 177	
	CK	UNUTMAZ, et al., "Antigen-independent Activation of Naive and Memory Resting T Cells by a Cytokine Combination," J. Exp. Med., 1994, 1159-1164, 180	
	CL	TOUGH, et al., "Induction of Bystander t Cell Proliferation by Viruses and Type I Interferon in Vivo," Science, 1996, 1947-1950, 272	
	CM	GOODACRE, et al., "Reduced Suppressor Cell Activity in Intestinal Lymphocytes from Patients with Crohn's Disease," Gastroenterology, 1982, 653-658, 82	
	CN	KAWAKAMI, et al., "Interleukin 4 Promotes the Growth of Tumor-Infiltrating Lymphocytes Cytotoxic for Human Autologous Melanoma," The Journal of Experimental Medicine, 1988, 2183-2191, 168	
	CO	BOISE, et al., "Growth Factors can Enhance Lymphocyte Survival Without Committing the Cell to Undergo Cell Division," Proc. Natl. Acad. Sci. USA, 1995, 5491-5495, 92	
	CP	SPITS, et al., "IL-4 Inhibits IL-2-Mediated Induction of Human Lymphokine-Activated Killer Cells, but not the Generation of Antigen-specific Cytotoxic T Lymphocytes in Mixed Leukocyte Cultures," The Journal of Immunology, 1988, 29-36, 141	
	CQ	SPITS, et al., "Recombinant Interleukin 4 Promotes the Growth of Human T Cells," The Journal of Immunology, 1987, 1142-1147, 139	
	CR	DULLEMEN, et al., "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," Gastroenterology, 1995, 129-135, 109	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.